iBio [IBIO] vs Alnylam [ALNY] Detailed Stock Comparison
TLDR: Quick Comparison Summary
We found some data (0 metrics), but not enough for a complete comparison. Metrics like P/E ratio, profitability, and financial health are still available in the detailed tabs below.
View Metrics Details
Vital Metrics Comparison
Currently, we don't have enough comparable metrics for these stocks. Please check the detailed tabs (Overview, Valuation, Financials) for more information.
iBio, Inc. vs Alnylam Pharmaceuticals Inc. Stock Performance Analysis
Loading Price Chart...
Performance Comparison
Short-term Returns
| Stock | 1D | 1W | 1M | 3M | 6M | YTD |
|---|---|---|---|---|---|---|
| iBio, Inc. | 0.00% | N/A | N/A | N/A | N/A | N/A |
| Alnylam Pharmaceuticals Inc. | 1.75% | -1.49% | 0.29% | -9.76% | -26.49% | -28.08% |
Long-term Returns
| Stock | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| iBio, Inc. | 45.56% | -99.94% | -99.97% | -99.51% | -99.74% | -99.74% |
| Alnylam Pharmaceuticals Inc. | -8.16% | 40.32% | 59.90% | 405.36% | 3,032.34% | 1,907.45% |
Performance & Financial Health Analysis: iBio, Inc. vs Alnylam Pharmaceuticals Inc.
| Metric | IBIO | ALNY |
|---|---|---|
| Market Information | ||
| Market Cap | N/A | $41.87B |
| Market Cap Category | N/A | Large cap |
| 10 Day Avg. Volume | N/A | 1,075,369 |
| 90 Day Avg. Volume | N/A | 1,141,756 |
| Last Close | $0.00 | $287.80 |
| 52 Week Range | $0.00 - $0.00 | $281.36 - $495.55 |
| % from 52W High | 0.00% | -41.92% |
| All-Time High | $17,400.00 (Oct 13, 2014) | $495.55 (Oct 20, 2025) |
| % from All-Time High | N/A | -41.92% |
| Growth Metrics | ||
| Quarterly Revenue Growth | N/A | 0.85% |
| Quarterly Earnings Growth | N/A | 0.85% |
| Financial Health | ||
| Profit Margin (TTM) | N/A | 0.08% |
| Operating Margin (TTM) | N/A | 0.12% |
| Return on Equity (TTM) | N/A | 0.73% |
| Debt to Equity (MRQ) | N/A | 376.19 |
| Cash & Liquidity | ||
| Book Value per Share (MRQ) | N/A | $5.96 |
| Cash per Share (MRQ) | N/A | $21.93 |
| Operating Cash Flow (TTM) | N/A | $524.08M |
| Levered Free Cash Flow (TTM) | N/A | $128.79M |
| Dividends | ||
| Last 12-Month Dividend Yield | N/A | N/A |
| Last 12-Month Dividend | N/A | N/A |
Valuation & Enterprise Metrics Analysis: iBio, Inc. vs Alnylam Pharmaceuticals Inc.
| Metric | IBIO | ALNY (Apr 24, 2026) |
|---|---|---|
| Price Ratios | ||
| P/E Ratio (TTM) | N/A | 132.73 |
| Forward P/E | N/A | 22.00 |
| PEG Ratio | N/A | 22.00 |
| Price to Sales (TTM) | N/A | 11.16 |
| Price to Book (MRQ) | N/A | 52.09 |
| Market Capitalization | ||
| Market Capitalization | N/A | $41.87B |
| Enterprise Value | N/A | $41.25B |
| Enterprise Value Metrics | ||
| Enterprise to Revenue | N/A | 11.11 |
| Enterprise to EBITDA | N/A | 74.03 |
| Risk & Other Metrics | ||
| Beta | N/A | 0.38 |
| Book Value per Share (MRQ) | N/A | $5.96 |
Financial Statements Comparison: iBio, Inc. vs Alnylam Pharmaceuticals Inc.
Financial Metrics
Loading Financial Charts...
Revenue
Operating Margin
Profit Margin
Long Term Debt
Income Flow Analysis
Financial Statements Comparison
Income Statement
| Metric | IBIO | ALNY (2025) |
|---|---|---|
| Revenue/Sales | N/A | 3.71B |
| Cost of Goods Sold | N/A | 681.87M |
| COGS % of Revenue | - | 18.4% |
| Gross Profit | N/A | 3.03B |
| Gross Margin | - | 81.6% |
| Research & Development | N/A | 1.32B |
| Operating Income (EBIT) | N/A | 501.58M |
| Operating Margin | - | 13.5% |
| EBITDA | N/A | 676.22M |
| EBITDA Margin | - | 18.2% |
| Pre-Tax Income | N/A | 323.15M |
| Pre-Tax Income % of Revenue | - | 8.7% |
| Income Tax | N/A | 9.41M |
| Income Tax % of Revenue | - | 0.3% |
| Net Income (Profit) | N/A | 313.75M |
| Profit Margin | - | 8.4% |
Balance Sheet & Liquidity Metrics
| Metric | IBIO | ALNY (2025) |
|---|---|---|
| Cash & Equivalents | N/A | 1.66B |
| Total Current Assets | N/A | 4.05B |
| Total Current Assets % of Revenue | - | 109.1% |
| Total Current Liabilities | N/A | 1.47B |
| Total Current Liabilities % of Revenue | - | 39.5% |
| Long-Term Debt | N/A | 1.23B |
| Long-Term Debt % of Revenue | - | 33.2% |
| Total Shareholders Equity | N/A | 789.18M |
| Retained Earnings | N/A | -6.70B |
| Retained Earnings % of Revenue | - | -180.5% |
| Property, Plant & Equipment | N/A | 384.79M |
Cash Flow Statement Comparison
| Metric | IBIO | ALNY (2025) |
|---|---|---|
| Operating Cash Flow | N/A | 639.50M |
| Operating Cash Flow % of Revenue | - | 17.2% |
| Capital Expenditures | N/A | -58.70M |
| Free Cash Flow | N/A | 465.38M |
| FCF Margin | - | 12.5% |
| Debt Repayment | N/A | -1.19B |
| Common Stock Repurchase | N/A | N/A |
Short Interest & Institutional Ownership Analysis
| Metric | IBIO | ALNY |
|---|---|---|
| Shares Short | N/A | 5.06M |
| Short Ratio | N/A | 4.49 |
| Short % of Float | N/A | 5.05% |
| Shares Outstanding | N/A | 132.38M |
| Float Shares | N/A | 132.07M |
| % Held by Insiders | N/A | 0.19% |
| % Held by Institutions | N/A | 101.05% |
| % Held by Public | N/A | -1.24% |
Dividend Analysis & Yield Comparison: iBio, Inc. vs Alnylam Pharmaceuticals Inc.
| Metric | IBIO | ALNY |
|---|---|---|
| Last 12-Month Dividend | N/A | N/A |
| Last 12-Month Dividend Yield | N/A | N/A |
| 3-Year Avg Annual Dividend | N/A | N/A |
| 3-Year Avg Dividend Yield | N/A | N/A |
| 3-Year Total Dividends | N/A | N/A |
| Ex-Dividend Date | N/A | N/A |